AQR Capital Management LLC cut its stake in shares of Applied Genetic Technologies Corporation (NASDAQ:AGTC) by 12.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 187,066 shares of the biotechnology company’s stock after selling 26,622 shares during the period. AQR Capital Management LLC owned approximately 1.03% of Applied Genetic Technologies Corporation worth $1,290,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. CAPROCK Group Inc. boosted its stake in Applied Genetic Technologies Corporation by 55.8% in the first quarter. CAPROCK Group Inc. now owns 17,215 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 6,165 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Applied Genetic Technologies Corporation during the first quarter valued at $123,000. Wells Fargo & Company MN boosted its stake in Applied Genetic Technologies Corporation by 1.1% in the first quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 200 shares during the period. Highbridge Capital Management LLC purchased a new stake in Applied Genetic Technologies Corporation during the fourth quarter valued at $191,000. Finally, Smith Asset Management Group LP purchased a new stake in Applied Genetic Technologies Corporation during the first quarter valued at $141,000. 61.52% of the stock is owned by institutional investors and hedge funds.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) traded up 11.11% during trading on Friday, hitting $5.00. 229,593 shares of the company were exchanged. Applied Genetic Technologies Corporation has a 12 month low of $4.50 and a 12 month high of $17.00. The company has a market capitalization of $90.38 million, a price-to-earnings ratio of 11.93 and a beta of 1.68. The company has a 50-day moving average of $5.04 and a 200-day moving average of $6.24.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last issued its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.04. Applied Genetic Technologies Corporation had a return on equity of 6.62% and a net margin of 17.61%. The company had revenue of $8.39 million for the quarter, compared to analyst estimates of $10.39 million. During the same period last year, the company posted $0.11 EPS. The business’s revenue for the quarter was down 30.1% on a year-over-year basis. Analysts forecast that Applied Genetic Technologies Corporation will post $0.33 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “AQR Capital Management LLC Has $1.29 Million Position in Applied Genetic Technologies Corporation (AGTC)” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/05/aqr-capital-management-llc-has-1-29-million-position-in-applied-genetic-technologies-corporation-agtc.html.

Several research firms have recently weighed in on AGTC. HC Wainwright set a $16.00 price target on shares of Applied Genetic Technologies Corporation and gave the company a “buy” rating in a research note on Saturday, June 10th. Zacks Investment Research raised shares of Applied Genetic Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. Cantor Fitzgerald set a $15.00 price objective on shares of Applied Genetic Technologies Corporation and gave the stock a “hold” rating in a research report on Wednesday, May 10th. ValuEngine cut shares of Applied Genetic Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Stifel Nicolaus lowered their price objective on shares of Applied Genetic Technologies Corporation from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, May 11th. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $13.81.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Institutional Ownership by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.